



December 03, 2025

To,
The General Manager-Listing,
Corporate Relations Department BSE Limited
P.J. Towers, Dalal Street
Mumbai – 400 001

Dear Sir/Madam

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Receipt of Authorization Letter from Integra Medical Devices India Private Limited.

Shukra Pharmaceuticals Limited ("the Company") is pleased to inform that it has received an Authorization Letter on December 03, 2025, from Integra Medical Devices India Private Limited, authorising the Company to act as the Authorized Distributor for all DGAFMS (Directorate General Armed Forces Medical Services) purchases across India.

As per the authorization, Shukra Pharmaceuticals Limited is empowered to:

1. Promote, market, and supply the medical equipment and devices of Integra Medical Devices India Private Limited for all DGAFMS-affiliated projects across Defence Hospitals, Commands, and related Defence Organisations Pan-India.
2. Operate as the official distributor for all DGAFMS-related procurement activities initiated from the date of issuance of the authorization letter.
3. Collaborate closely with Integra Lifesciences on all projects, including adherence to mutually agreed commercial terms, compliance norms, and ethical business standards.

The authorization is valid till 31 December 2026, unless terminated earlier as per the terms of the letter.

Impact on Shukra Pharmaceuticals & Benefit to Shareholders

This strategic authorization:

Strengthens Shukra Pharma's presence in the high-value Defence Healthcare segment, a space known for consistent demand and long-term contracts.

* Expands the Company's product portfolio into advanced medical devices through partnership with Integra Medical Devices India Private Limited.

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

* Is expected to enhance revenue visibility and improve margins owing to premium medical device offerings supplied to DGAFMS.

* Positions Shukra Pharma as a credible partner for future Government and Defence-sector collaborations, creating opportunities for sustainable business growth.

The Company believes this collaboration will positively contribute to long-term shareholder value through diversification, improved market positioning, and expansion into a stable procurement ecosystem.

This disclosure is made in compliance with Regulation 30 of SEBI LODR Regulations, 2015.

The above information is submitted for the benefit of investors and stakeholders.

For, Shukra Pharmaceuticals Limited

Dakshesh Shah
Managing Director
DIN: 00561666



CIN : L24231GJ1993PLC019079